Beiersdorf AG has acquired a majority stake in S-Biomedic NV, a Belgium-based life-science company focused on skin microbiome research. Beiersdorf had earlier invested in S-Biomedic in 2018 as part of its corporate venture capital activities.

A purchase price was not disclosed.

S-Biomedic will continue to be managed as a standalone entity under Beiersdorf’s existing microbiome program and will complement the company’s own research activities in this field.

The company was founded by Veronika Oudova and Bernhard Paetzold in 2014.

“As skin care experts, research has been at the heart of what we have been doing for 140 years. Therefore, the acquisition of S-Biomedic is an ideal strategic fit to drive our innovation power even further in line with our C.A.R.E.+ strategy. Together with the pioneers of S-Biomedic we are taking skin care to the next level and will foster the development of solutions for unmet consumer needs,” said Dr. Gitta Neufang, senior vice president of R&D at Beiersdorf.

Jörn Hendrik Reuter, manager microbiome accelerator at Beiersdorf, said the advances of S-Biomedic in biomedical research complement Beiersdorf’s “efforts in this field and open the door to develop products that work in harmony with the natural skin processes.”